Protective immune responses against foot-and-mouth disease virus by vaccination with a DNA vaccine expressing virus-like particles

Viral Immunology

Volumn 20, Issue 3, 2007, Pages 429-440

  Jin, Huali ^a   Xiao, Wang ^a   Xiao, Chong ^a   Yu, Yang ^a   Kang, Youmin ^a   Du, Xiaogang ^a   Wei, Xuefeng ^b   Wang, Bin ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b Jinyu Group Corporation   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G; PROTEIN VP1; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DNA IMMUNIZATION; DNA TRANSFECTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GENETIC ENGINEERING; HELA CELL; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; VIRUS LIKE AGENT;

ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; HEPATITIS B CORE ANTIGENS; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; VACCINES, DNA; VACCINES, VIROSOME;

ANIMALIA; FOOT-AND-MOUTH DISEASE VIRUS; HEPATITIS B VIRUS; MIRIDAE; MUS;

EID: 35348853993     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2007.0031     Document Type: Article

References (41)

1. Aberle JH, Aberle SW, Allison SL, Stiasny K, Ecker M, Mandl CW, Berger R, and Heinz FX: A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms. J Immunol 1999;163:6756-6761.
2. Beesley KM, Francis MJ, Clarke BE, Beesley JE, Dopping-Hepenstal PJ, Clare JJ, Brown F, and Romanos MA: Expression in yeast of amino-terminal peptide fusions to hepatitis B core antigen and their immunological properties. Biotechnology 1990;8:644-649.
3. Bittle JL, Houghten RA, Alexander H, Shinnick TM, Sutcliffe JG, Lerner RA, Rowlands DJ, and Brown F: Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 1982;298:30-33.
4. Boyle JS, Koniaras C, and Lew AM: Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: Cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol 1997;9:1897-1906.
5. Chengalvala MV, Bhat RA, Bhat BM, Vernon SK, and Lubeck MD: Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid. Vaccine 1999;17:1035-1041.
6. Ciarlet M, Crawford SE, Barone C, Bertolotti-Ciarlet A, Ramig RF, Estes MK, and Conner ME: Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol 1998;72:9233-9246.
7. Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, Syred AD, Highfield PE, Rowlands DJ, and Brown F: Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 1987;330:381-384.
8. Ferris NP, Kitching RP, Oxtoby JM, Philpot RM, and Rendle R: Use of inactivated foot-and-mouth disease virus antigen in liquid-phase blocking ELISA. J Virol Methods 1990;29:33-41.
9. Guo H, Liu Z, Sun S, Bao H, Chen Y, Liu X, and Xie Q: Immune response in guinea pigs vaccinated with DNA vaccine of foot-and-mouth disease virus O/China99. Vaccine 2005;23:3236-3242.
10. Hamblin C, Barnett IT, and Hedger RS: A new enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against foot-and-mouth disease virus. I. Development and method of ELISA. J Immunol Methods 1986;93:115-121.
11. Harvey, Tracey J, Anraku I, Linedale R, Harrich D, Mackenzie J, Suhrbier A, and Khromykh AA: Kunjin virus replicon vectors for human immunodeficiency virus vaccine development. J Virol 2003;77:7796-7803.
12. Huang Y, Babiuk LA, and van Drunen Littel-van den Hurk S: Immunization with a bovine herpesvirus 1 glycoprotein B DNA vaccine induces cytotoxic T-lymphocyte responses in mice and cattle. J Gen Virol 2005;86:887-898.
13. Huang Y, Liang W, Wang Y, Zhou Z, Pan A, Yang X, Huang C, Chen J, and Zhang D: Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco. Viral Immunol 2005;18:668-677.
14. Jin H, Li Y, Ma Z, Zhang F, Xie Q, Gu D, and Wang B: Effect of chemical adjuvants on DNA vaccination. Vaccine 2004;22:2925-2935.
15. Jin H, Xiao C, Chen Z, Kang Y, Ma Y, Zhu K, Xie Q, Tu Y, Yu Y, and Wang B: Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. Biochem Biophys Res Commun 2005;328:979-986.
16. Kratz, PA, Bottcher B, and Nassal M: Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA 1999;96:1915-1920.
17. Kunke D, Broucek J, Kutinova L, Nemeckova S, Ludvikova V, Strnad I, Kramosil J, Nemcova J, Schramlova J, and Simonova V: Vaccinia virus recombinants co-expressing hepatitis B virus surface and core antigens. Virology 1993;195:132-139.
18. Layton GT, Harris SJ, Gearing AJ, Hill-Perkins M, Cole JS, Griffiths JC, Burns NR, Kingsman AJ, and Adams SE: Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J Immunol 1993;151:1097-1107.
19. Li Y, Aggarwal N, Takamatsu HH, Sterling CM, Voyce C, and Barnett PV: Enhancing immune responses against a plasmid DNA vaccine encoding a FMDV empty capsid from serotype O. Vaccine 2006;24:4602-4606.
20. Lyons AB, and Parish CR: Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994;171:131-137.
21. Marsac D, Loirat D, Petit C, Schwartz O, and Michel ML: Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. J Virol 2002;76:7544-7553.
22. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, and Hilleman MR: Human hepatitis B vaccine from recombinant yeast. Nature 1984;307:178-180.
23. Miyanohara A, Imamura T, Araki M, Sugawara K, Ohtomo N, and Matsubara K: Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: Synthesis of two polypeptides translated from different initiation codons. J Virol 1986;59:176-180.
24. Montefiori DC, Safrit JT, Lydy SL, Barry AP, Bilska M, Vo HTT, Klein M, Tartaglia J, Robinson HL, and Rovinski B: Induction of neutralizing antibodies and Gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol 2001;75:5879-5890.
25. Moraes MP, Mayr GA, Mason PW, and Grubman MJ: Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 2002;20:1631-1639.
26. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, and Liang JT: Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 2003;100:6753-6758.
27. Netter HJ, Macnaughton TB, Woo W-P, Tindle R, and Gowans EJ: Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol 2001;75:2130-2141.
28. Oehen S, and Brduscha-Riem K: Differentiation of naive CTL to effector and memory CTL: Correlation of effector function with phenotype and cell division. J Immunol 1998;161:5338-5346.
29. Pacheco JM, Brum MC, Moraes MP, Golde WT, and Grubman MJ: Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 2005;337:205-209.
30. Pumpens P, Borisova GP, Crowther RA, and Grens E: Hepatitis B virus core particles as epitope carriers. Intervirology 1995;38:63-74.
31. Robbins JB, Schneerson R, and Szu SC: Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum [perspective]. J Infect Dis 1995;171:1387-1398.
32. Schodel F, Moriarty AM, Peterson DL, Zheng JA, Hughes JL, Will H, Leturcq DJ, McGee JS, and Milich DR: The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol 1992;66:106-114.
33. Schodel F, Wirtz R, Peterson D, Hughes J, Warren R, Sadoff J, and Milich D: Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med 1994;180:1037-1046.
34. Sedlik C, Dadaglio G, Saron MF, Deriaud E, Rojas M, Casal SI, and Leclerc C: In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 2000;74:5769-5775.
35. Sedlik C, Saron MF, Sarraseca J, Casal I, and Leclerc C: Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic cells. Proc Natl Acad Sci USA 1997;94:7503-7508.
36. Storni T, Lechner F, Erdmann I, Bachi T, Jegerlehner A, Dumrese T, Kundig TM, Ruedl C, and Bachmann MF: Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 2002;168:2880-2886.
37. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, and Bachmann MF: Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004;172:1777-1785.
38. Tu Y, Zhang X, Jin H, Yang F, Liu M, Zhang F, and Wang B: Comparisons of the expression efficiencies and immune effects of two eukaryotic vectors encoding E2 gene. J China Agric Univ 2005;10:37-41.
39. van Lierop MJ, van Maanen K, Meloen RH, Rutten VP, de Jong MA, and Hensen EJ: Proliferative lymphocyte responses to foot-and-mouth disease virus and three FMDV peptides after vaccination or immunization with these peptides in cattle. Immunology 1992;75:406-413.
40. Vasantha S, Antony A, and Lal SM: Liposome encapsulated subunit (VP1) and virion vaccines against foot-and-mouth disease. Acta Virol 1987;31:109-115.
41. Ward G, Rieder E, and Mason PW: Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. J Virol 1997;71:7442-7447.